Free Trial

Collegium Pharmaceutical (COLL) Competitors

Collegium Pharmaceutical logo
$35.36 +0.51 (+1.46%)
Closing price 04:00 PM Eastern
Extended Trading
$35.38 +0.02 (+0.07%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

COLL vs. SRRK, VKTX, MIRM, LNTH, ADMA, ACAD, ZLAB, QURE, CGON, and AAPG

Should you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Scholar Rock (SRRK), Viking Therapeutics (VKTX), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), ADMA Biologics (ADMA), ACADIA Pharmaceuticals (ACAD), Zai Lab (ZLAB), uniQure (QURE), CG Oncology (CGON), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.

Collegium Pharmaceutical vs. Its Competitors

Scholar Rock (NASDAQ:SRRK) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Scholar Rock has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

91.1% of Scholar Rock shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 2.5% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Scholar Rock currently has a consensus price target of $48.50, suggesting a potential upside of 72.17%. Collegium Pharmaceutical has a consensus price target of $42.33, suggesting a potential upside of 19.72%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Collegium Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scholar Rock
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
3.07
Collegium Pharmaceutical
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, Scholar Rock had 7 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 9 mentions for Scholar Rock and 2 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.69 beat Scholar Rock's score of 0.25 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scholar Rock
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Collegium Pharmaceutical
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Collegium Pharmaceutical has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar Rock$33.19M81.59-$246.29M-$2.91-9.68
Collegium Pharmaceutical$631.45M1.76$69.19M$1.0434.00

Collegium Pharmaceutical has a net margin of 5.13% compared to Scholar Rock's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 97.28% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Scholar RockN/A -127.11% -90.09%
Collegium Pharmaceutical 5.13%97.28%13.87%

Summary

Collegium Pharmaceutical beats Scholar Rock on 9 of the 17 factors compared between the two stocks.

Get Collegium Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COLL vs. The Competition

MetricCollegium PharmaceuticalMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.10B$2.66B$6.17B$10.69B
Dividend YieldN/A57.75%5.72%4.83%
P/E Ratio34.0023.5929.1427.22
Price / Sales1.76777.17580.06129.95
Price / Cash2.82171.3937.5161.65
Price / Book4.985.4112.476.59
Net Income$69.19M$33.06M$3.32B$276.14M
7 Day Performance9.92%1.33%1.87%0.01%
1 Month Performance-1.09%10.15%8.40%3.60%
1 Year Performance-3.02%-2.20%63.49%32.76%

Collegium Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COLL
Collegium Pharmaceutical
3.7812 of 5 stars
$35.36
+1.5%
$42.33
+19.7%
-9.3%$1.10B$631.45M34.00210Analyst Downgrade
SRRK
Scholar Rock
4.5083 of 5 stars
$34.28
-13.1%
$47.00
+37.1%
-8.6%$3.79B$33.19M-11.78140Analyst Forecast
Gap Down
High Trading Volume
VKTX
Viking Therapeutics
4.0065 of 5 stars
$33.91
+1.0%
$86.42
+154.8%
-48.7%$3.77BN/A-22.1620Upcoming Earnings
MIRM
Mirum Pharmaceuticals
4.1416 of 5 stars
$72.17
-0.7%
$76.50
+6.0%
+85.1%$3.65B$336.89M-59.64140
LNTH
Lantheus
4.5914 of 5 stars
$54.59
+2.0%
$74.50
+36.5%
-51.5%$3.64B$1.53B14.52700Trending News
ADMA
ADMA Biologics
3.676 of 5 stars
$14.55
+0.1%
$27.67
+90.1%
-6.9%$3.47B$426.45M16.92530Positive News
ACAD
ACADIA Pharmaceuticals
3.9085 of 5 stars
$20.06
flat
$29.12
+45.2%
+36.9%$3.38B$957.80M15.08510Analyst Forecast
Gap Up
ZLAB
Zai Lab
2.6302 of 5 stars
$31.23
+3.3%
$56.35
+80.4%
+4.5%$3.38B$398.99M-15.311,869Gap Up
QURE
uniQure
2.1488 of 5 stars
$62.02
+0.7%
$71.75
+15.7%
+895.6%$3.38B$27.12M-15.82500
CGON
CG Oncology
1.7821 of 5 stars
$42.96
-0.7%
$58.82
+36.9%
+19.6%$3.30B$1.14M-24.2761
AAPG
Ascentage Pharma Group International
N/A$36.45
+4.3%
N/AN/A$3.26B$390.60M0.00600Gap Down

Related Companies and Tools


This page (NASDAQ:COLL) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners